Advertisement
open access
Medical Conferences
Conference Reports
2024 Medicom Conference Planning
Conference Proceedings
Disease Areas
Medical News
Multimedia
Podcast Channel
Videos
Webinar
About
Conference Proceedings
Home
>
Haematology
>
ASH 2021 Focus on CAR T-Cell Therapy
ASH 2021 Focus on CAR T-Cell Therapy
American Society of Hematology
Atlanta, 11–14 December 2021
Table of Contents
Table of Contents
Featured articles
Welcome to our Focus Edition on CAR T-cell therapy news
ASH 2021 Focus on CAR T-Cell Therapy Podcast
Presented By
Dr Rachel Giles, Medicom
Axi-cel improved event-free survival in relapsed/refractory large B-cell lymphoma
Expert
Dr Frederick Locke, Moffitt Cancer Cancer, Tampa, Florida, USA
CAR T-cell Therapy
Most re-hospitalisations within first month from CAR T-cell infusion
Expert
Dr Kelly Kenzik, Institute for Cancer Outcomes and Survivorship, University of Alabama, USA
CD22-directed CAR T-cell therapy safe and well-tolerated in R/R LBCL
Expert
Dr Matthew J. Frank, Stanford University School of Medicine, USA
High rate of rapid and complete responses with axi-cel in high-risk large B-cell lymphoma
Expert
Dr Sattva S. Neelapu, MD Anderson Cancer Center, Houston, USA
Novel anti-CD19 plus lenalidomide prolonged survival in R/R DLBCL
Expert
Dr Grzegorz Nowakowski, Mayo Clinic, Rochester, USA
Liso-cel superior to standard-of-care as second-line therapy in large B-cell lymphoma
Expert
Dr Manali Kamdar, University of Colorado Cancer Center, Denver, USA
CIRS is predictive of outcomes in CAR T-cell recipients with R/R DLBCL
Expert
Dr Geoffrey Shouse, City of Hope Comprehensive Cancer Center, USA
Axi-cel more effective but tisa-cel less toxic in large B-cell lymphoma
Expert
Dr Emmanuel Bachy, Hospices Civils de Lyon, France
Axi-cel improved event-free survival in relapsed/refractory large B-cell lymphoma
Expert
Dr Frederick Locke, Moffitt Cancer Cancer, Tampa, Florida, USA
Comparable outcomes with second-line tisa-cel versus standard-of-care for relapsed/refractory aggressive NHL
Expert
Dr Michael R. Bishop, David and Etta Jonas Center for Cellular Therapy, University of Chicago, USA
Improved QoL with axi-cel versus standard-of-care in R/R LBCL
Expert
Dr Mahmoud Elsawy, Dalhousie University, Halifax, USA